A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MT1 / membrane type 1

[Related PubMed/MEDLINE]
Total Number of Papers: 104
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MT1  (>> Co-occurring Abbreviation)
Long Form:   membrane type 1
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Proamyloidogenic effects of membrane type 1 matrix metalloproteinase involve MMP-2 and BACE-1 activities, and the modulation of APP trafficking. AD, APP, BACE1, MMP
2018 Processed eggshell membrane powder regulates cellular functions and increase MMP-activity important in early wound healing processes. alpha-SMA, ESM, MMP-2, PEP, TIMP-2
2016 p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer. BM, DCIS
2014 EMMPRIN co-expressed with matrix metalloproteinases predicts poor prognosis in patients with osteosarcoma. EMMPRIN, MMPs, OS and DFS
2014 Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload. LV, MMPs, PO, WT
2014 Tetraarsenic oxide-induced inhibition of malignant glioma cell invasion in vitro via a decrease in matrix metalloproteinase secretion and protein kinase B phosphorylation. GSK-3beta, MMP, PTEN
2014 The effect of imiquimod on matrix metalloproteinases and tissue inhibitors of metalloproteinases in malignant melanoma cell invasion. MMPs, TIMPs
2013 A monoclonal antibody interferes with TIMP-2 binding and incapacitates the MMP-2-activating function of multifunctional, pro-tumorigenic MMP-14/MT1-MMP. MMPs, MT, TIMP-2
2013 Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma. MMPs, RT-PCR, TIMPs
10  2013 MT1-MMP expression level status dictates the in vitro action of lupeol on inflammatory biomarkers MMP-9 and COX-2 in medulloblastoma cells. COX, MMPs, PMA
11  2013 MT1-MMP regulates MMP-2 expression and angiogenesis-related functions in human umbilical vein endothelial cells. MMPs
12  2013 Quantitative FRET imaging to visualize the invasiveness of live breast cancer cells. FRET, MMPs
13  2012 Adenosine A3 receptor stimulation reduces muscle injury following physical trauma and is associated with alterations in the MMP/TIMP response. MMPs, TA
14  2012 All-trans-retinoic acid and the glycolipid alpha-galactosylceramide combined reduce breast tumor growth and lung metastasis in a 4T1 murine breast tumor model. alpha-GalCer, MMP, RA
15  2012 Cleavage of hepatocyte growth factor activator inhibitor-1 by membrane-type MMP-1 activates matriptase. Con A, HAI-1, uPA
16  2012 Cyclosporine-A inhibits MMP-2 and -9 activities in the presence of Porphyromonas gingivalis lipopolysaccharide: an experiment in human gingival fibroblast and U937 macrophage co-culture. CsA, LPS
17  2012 Nascent vessel elongation rate is inversely related to diameter in in vitro angiogenesis. MMPs
18  2011 Exosite interactions impact matrix metalloproteinase collagen specificities. cat, cat, fTHPs, MMP
19  2011 Hyaluronic acid and thrombin upregulate MT1-MMP through PI3K and Rac-1 signaling and prime the homing-related responses of cord blood hematopoietic stem/progenitor cells. CB, G-CSF, HSPC, MMPs, SDF
20  2011 Matrix metalloproteinase 2 promotes cell growth and invasion in colorectal cancer. CRC, MMP2, VEGF
21  2011 Radiation-enhancement of MDA-MB-231 breast cancer cell invasion prevented by a cyclooxygenase-2 inhibitor. COX-2, MMP-2
22  2011 Regulation of MT1-MMP and MMP-2 by leptin in cardiac fibroblasts involves Rho/ROCK-dependent actin cytoskeletal reorganization and leads to enhanced cell migration. MMP, Rho, ROCK
23  2011 The effects of a plant proteinase inhibitor from Enterolobium contortisiliquum on human tumor cell lines. hMSCs, MMP
24  2010 Degradation of soluble and fibrillar amyloid beta-protein by matrix metalloproteinase (MT1-MMP) in vitro. MMP2
25  2010 Membrane type 1 matrix metalloproteinase detection in tumors, using the iodinated endogenous [123I]-tissue inhibitor 2 of metalloproteinases as imaging agent. MMPs, rhTIMP-2, TIMP-2
26  2010 Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP. MT1-MMP, PC
27  2010 Prognostic value of membrane type 1 and 2 matrix metalloproteinase expression and gelatinase A activity in bladder cancer. MMPs
28  2010 The HGF/c-Met axis synergizes with G-CSF in the mobilization of hematopoietic stem/progenitor cells. BM, ECM, FACS, G-CSF, HGF, HSPCs, MMPs, PB, WBC
29  2010 The ss1-integrin-dependent function of RECK in physiologic and tumor angiogenesis. Cip1, HUVEC, MMP, RECK
30  2010 TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. ECM, MI, MMPs, TIMPs
31  2009 Bone sialoprotein does not interact with pro-gelatinase A (MMP-2) or mediate MMP-2 activation. BSP
32  2009 Matrix metalloproteinase-9 expression and release from skin fibroblasts interacting with keratinocytes: Upregulation in response to sulphur mustard. MMPs, NHDF, SM
33  2009 MT1-MMP- and Cdc42-dependent signaling co-regulate cell invasion and tunnel formation in 3D collagen matrices. MMP, SCITs
34  2009 Tissue-type plasminogen activator deficiency attenuates peritoneal fibrosis in mice. alpha-SMA, MMP, PA, PF, TGF-beta1, TIMP, tPA
35  2009 Troglitazone inhibits vascular endothelial growth factor-induced angiogenic signaling via suppression of reactive oxygen species production and extracellular signal-regulated kinase phosphorylation in endothelial cells. ERK, MMP, PPARgamma, ROS, Trog, VEGF
36  2008 Cdc42 and RhoA have opposing roles in regulating membrane type 1-matrix metalloproteinase localization and matrix metalloproteinase-2 activation. MMP, VEGF
37  2008 Cocoa procyanidins inhibit expression and activation of MMP-2 in vascular smooth muscle cells by direct inhibition of MEK and MT1-MMP activities. CPF, MEK, MMP, VSMC
38  2008 Effect of hormones on matrix metalloproteinases gene regulation in human aortic smooth muscle cells. EST, MMPs, PROG, RT-PCR, TIMP, VSMCs
39  2008 Gelatinase (MMP-2 and -9) expression profiles during gestation in the bovine endometrium. EMMPRIN, MMPs, TIMP
40  2008 JNK as a positive regulator of angiogenic potential in endothelial cells. JNK, MMP-2
41  2008 The arthritis severity locus Cia5d is a novel genetic regulator of the invasive properties of synovial fibroblasts. FLS, MMPs, RA
42  2008 The inactive 44-kDa processed form of membrane type 1 matrix metalloproteinase (MT1-MMP) enhances proteolytic activity via regulation of endocytosis of active MT1-MMP. MT1-MMP
43  2007 Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. MMPs, RT-PCR, TIMPs
44  2007 Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1; gelatinase-selective inhibitors. MMPs, TIMPs
45  2007 Differential expression of matrix metalloproteinases and inhibitors in developing rat lung mesenchymal and epithelial cells. AECs, ATII, MMPs, PN, TIMPs
46  2007 Docosahexaenoic acid induces proteasome-dependent degradation of beta-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2. COX-2, DHA, TCF
47  2007 Evidence for a cooperative role of gelatinase A and membrane type-1 matrix metalloproteinase during Xenopus laevis development. ECM, GelA, MMPs
48  2007 Immunohistochemical observation of amniotic membrane patching on a corneal alkali burn in vivo. alpha-SMA, AM, MMP
49  2007 Induction of matrix metalloproteinase-2 enhances systemic arterial contraction after hypoxia. big ET-1, CTT, MMP-2, PE
50  2007 Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung. ADC, MMP, NSCLC, RECK, RT-PCR, SCC
51  2007 The Wnt signal transduction pathway in stem cells and cancer cells: influence on cellular invasion. EMT, hMSC, MMPs
52  2006 Changes in matrix metalloproteinase 2 activities in amniochorions during premature rupture of membranes. ECM, MMPs, TIMP
53  2006 Effects of tissue inhibitor of metalloproteinase 2 deficiency on aneurysm formation. AAA, MMP, TIMP, TIMP-2
54  2006 Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. DCIS
55  2006 Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice. MMP
56  2006 Intracellular localization of matrix metalloproteinases and their inhibitors in cultured tumor cell lines: flow cytometric analysis. MMPs, TIL
57  2006 Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. BM, CB, HGF, MMPs, MSCs, SDF, VE
58  2006 Production of matrix metalloproteinases in human cultured mast cells: involvement of protein kinase C-mitogen activated protein kinase kinase-extracellular signal-regulated kinase pathway. ERK, GM-CSF, HCMC, MEK, MMPs, PMA, TIMPs
59  2006 Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity. ---
60  2006 The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. DSS, EOC, MMP
61  2005 High-density lipoproteins prevent the oxidized low-density lipoprotein-induced epidermal [corrected] growth factor receptor activation and subsequent matrix metalloproteinase-2 upregulation. HDL, HNE, oxLDL, ROS
62  2005 How do stem cells find their way home? BM, ECM, LFA-1, SCF, SDF-1
63  2005 MAPK signaling regulates endothelial cell assembly into networks and expression of MT1-MMP and MMP-2. MMP
64  2005 Mutational and structural analyses of the hinge region of membrane type 1-matrix metalloproteinase and enzyme processing. ---
65  2004 Activation of MMP-2 in response to vascular injury is mediated by phosphatidylinositol 3-kinase-dependent expression of MT1-MMP. MMPs, PI3K, SMC
66  2004 Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. MMPIs, MMPs
67  2004 Co-operative interactions between NFAT (nuclear factor of activated T cells) c1 and the zinc finger transcription factors Sp1/Sp3 and Egr-1 regulate MT1-MMP (membrane type 1 matrix metalloproteinase) transcription by glomerular mesangial cells. MT1-MMP
68  2004 Experimental hindlimb ischemia leads to neutrophil-mediated increases in gastrocnemius MMP-2 and -9 activity: a potential mechanism for ischemia induced MMP activation. ANOVA, HI, MMP, ND, PMNs
69  2004 Gelatinase expression in ocular surface disorders. MMP, RT-PCR
70  2004 Interactions of proteases, protease inhibitors, and the beta1 integrin/laminin gamma3 protein complex in the regulation of ectoplasmic specialization dynamics in the rat testis. AJs, MMP, TIMP
71  2004 Red wine polyphenolic compounds strongly inhibit pro-matrix metalloproteinase-2 expression and its activation in response to thrombin via direct inhibition of membrane type 1-matrix metalloproteinase in vascular smooth muscle cells. MMPs, RWPCs, VSMCs
72  2003 Expression of matrix metalloproteinases 2 and 7 in tumor cells correlates with the World Health Organization classification subtype and clinical stage of thymic epithelial tumors. MMPs, TIMP-2
73  2003 Gestational profile of matrix metalloproteinases in rat uterine artery. MMPs, TIMPs
74  2003 Interleukin 10 blocks matrix metalloproteinase-2 and membrane type 1-matrix metalloproteinase synthesis in primary human prostate tumor lines. IGF, IL, MMP-2
75  2003 Matrix metalloproteinase regulation of sphingosine-1-phosphate-induced angiogenic properties of bone marrow stromal cells. Con A, EC, MMP, MSC, S1P
76  2003 Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix. HMVECs, MMP-1, PCR, TIMP-1, VEGF
77  2003 Modulation of matrix gelatinases and metalloproteinase-activating process in acute kidney rejection. MMP, TIMP
78  2003 Pathogenic A beta induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascular smooth muscle cells. CAA, HCSM, MMP-2
79  2003 Temporal expression and activation of matrix metalloproteinases-2, -9, and membrane type 1-matrix metalloproteinase following acute hindlimb ischemia. HI, MMP, PMNs
80  2003 The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells. MMPs, TIMPs
81  2003 TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. MMP, MMP-2, TIMP, TIMP-2
82  2002 Gene expression of adhesion molecules and matrix metalloproteinases in endometriosis. MMPs
83  2002 Involvement of matrix metalloproteinases in the adipose conversion of 3T3-L1 preadipocytes. MMPs
84  2002 Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. CCR, MCP, MMP
85  2002 Membrane-type matrix metalloproteinases mediate curcumin-induced cell migration in non-tumorigenic colon epithelial cells differing in Apc genotype. APC, EGF, HGF, IMCE, MMP, YAMC
86  2002 Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. MMPs, TIMPs
87  2002 Relationship between expression of matrix metalloproteinases and migration of epidermal and in vitro generated Langerhans cells. BB, eLC, iLC, LC, MMP-9, TNF-alpha
88  2002 Survivin gene expression in endometriosis. MMP
89  2002 Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Ln-5, MMPs
90  2002 The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. MMPs
91  2002 The significance of membrane type 1 metalloproteinase in structural involution of human corpora lutea. MMP
92  2001 Elevated furin expression in aggressive human head and neck tumors and tumor cell lines. HNSCCs, MMP, PCs
93  2001 Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart. MMPs
94  2001 Extracellular matrix degradation and the role of hepatic stellate cells. HSCs, MMPs, uPA
95  2001 Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. pro-MMP, TIMP-2
96  2001 MT1-MMP in rat testicular development and the control of Sertoli cell proMMP-2 activation. ---
97  2001 Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. ECM, MMPs, NF-kappaB, OPN
98  2001 Pterygia pathogenesis: corneal invasion by matrix metalloproteinase expressing altered limbal epithelial basal cells. MMPs
99  2001 Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. MMP, TIMPs
100  2000 Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressiveness. T/N